Optimizing Bispecific Use in Multiple Myeloma Treatment
A key opinion leader explores the integration of bispecifics into MM therapy regimens.
Stay updated with breaking news from Master Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A key opinion leader explores the integration of bispecifics into MM therapy regimens.
Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.
Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.